SAMD9L

Across TCGA pan-cancer cohorts, SAMD9L mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SAMD9L’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SAMD9L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SAMD9L is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

HNSC, LSCC, and PDAC are the cancer types where SAMD9L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SAMD9L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.581	<.001	8	view →
LSCC	Male	II,III,IV	−0.336	<.001	7	view →
PDAC	Female	All	+0.700	<.001	6	view →
COAD	Male	All	+0.463	.001	4	view →
LUAD	All	All	−0.161	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SAMD9L–HNSC

Open the HNSC breakdown →